ASPIRE for unprecedented benefit with carfilzomib in MM
نویسندگان
چکیده
منابع مشابه
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study
A primary analysis of the ASPIRE study found that the addition of carfilzomib to lenalidomide and dexamethasone (carfilzomib group) significantly improved progression-free survival (PFS) compared with lenalidomide and dexamethasone alone (control group) in patients with relapsed multiple myeloma (RMM). This post hoc analysis examined outcomes from ASPIRE in patients categorised by age. In the c...
متن کاملASPIRE: Iterative Specification Synthesis for Security
How to perform a systematic security analysis of complex applications is a challenging and open question. Approaches based on formal verification are impeded due to the lack of application specifications. To address this challenge, we propose a framework, called ASPIRE, that enables analysts to automatically synthesize specifications from examples such as application input-output examples and s...
متن کاملCarfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement
The dismal outcome of pleuropericardial extramedullary multiple myeloma (EMM) reflects both the selection of resistant disease and absence of useful drugs. Carfilzomib and dexamethasone should be explored in advanced EMM patients, even for bortezomib-resistant patients, as may provide much longer overall survival than previously reported treatments.
متن کاملAdipoRon may be benefit for atherosclerosis prevention
Atherosclerosis has serious role in coronary arteries disease,so it is important to establish effective strategies for prevention or even treatment of atherosclerosis. Adiponectin, as one of the most abundant adipokines, has insulin sensitivity, anti-inflammatory and anti-atherogenic properties. Disturbed adiponectin actions through its receptor, (AdipoR1 and AdipoR2) may be involved in atheros...
متن کاملCarfilzomib: a novel agent for multiple myeloma.
OBJECTIVES Carfilzomib is a new agent for the treatment of relapsed and refractory multiple myeloma (MM). This article presents a comprehensive overview of the pharmacokinetics, pharmacodynamics, dosing schedule, safety, efficacy, preparation and administration of carfilzomib, and its role in treating MM patients. KEY FINDINGS Carfilzomib is a selective proteasome inhibitor that differs struc...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Reviews Clinical Oncology
سال: 2014
ISSN: 1759-4774,1759-4782
DOI: 10.1038/nrclinonc.2014.228